NMT Capital
175 Washington Street, Norwell, MA, 02061, United States
Overview
NMT Capital (”Nexus”) is a globally oriented private equity firm and is currently managing investment funds based in Europe and in the US. Nexus’s portfolio companies are located in both North America and Europe and span the early to late stages of development. Nexus also acts as a consultant to various global investment banks, typically assisting them in sourcing and evaluating private medical companies seeking an acquirer, strategic partner, or growth capital. Nexus is managed by Principals who average more than 20 years of investment management/advisory experience in the fields of medical technology, life science, advanced materials, software, communications, and information technology. They are supported by Advisors and affiliates in Quincy (MA), San Francisco, London, Munich, Geneva, and Tokyo.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Medical
Investment portfolio
- Proterra
Participated · Series B · Nov 2012
Proterra is a Burlingame, California–based company that develops and produces battery-electric, heavy-duty transit buses aimed at lowering operating costs and emissions for municipal, university, and commercial fleet operators. Its core offering is a line of zero-emission buses supported by in-house battery and charging technologies. To date, the company has sold more than 400 vehicles to 39 transit agencies across 20 states, demonstrating growing market traction. Proterra operates manufacturing facilities in South Carolina and Los Angeles, with research and development centered at its Silicon Valley headquarters. Recent capital infusions are being directed toward expanding production capacity at these plants and accelerating R&D initiatives. Led by CEO Ryan Popple, the firm continues to scale operations to meet increasing demand for clean public transportation solutions. The company most recently secured $55 million in Series 6 funding following an oversubscribed $140 million Series 5 round earlier in the year.
Team
No current team members are available.